Activation cross sections of proton induced nuclear reactions on neodymium up to 65 MeV

Tárkányi, F.; Hermanne, Alex; Ditrói, F.; Takács, S.

doi:10.1007/s10967-017-5498-1

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other irradiation methods have been investigated on natural Nd targets and cross-sections have been measured for the 148 Nd(p,γ) 149 Pm, 150 Nd(p,2n) 149 Nd → 149 Pm, 148 Nd(d,n) 149 Pm, and 150 Nd(d,3n) 149 Pm nuclear reactions (Yang et al 2015 ; Tárkányi et al 2017 ; Lebeda et al 2014 , 2012 ; Tárkányi et al 2014 ). Measured cross-sections of these reactions are considerably lower than the well-established 148 Nd(n,γ) 149 Nd → 149 Pm nuclear reaction, and so have not seen routine use for 149 Pm production.…”

Section: Promethium : 149 ...mentioning

confidence: 99%

“…Specifically for the separation of 149 Pm from Nd, optimum separation was achieved when 0.18 M HNO 3 was used for elution of Nd and 149 Pm was stripped from the column with 1.5 M HNO 3 , resulting in a separation efficiency of 98.4%. The 149 Pm was then (Yang et al 2015;Tárkányi et al 2017;Lebeda et al 2014Lebeda et al , 2012Tárkányi et al 2014). Measured cross-sections of these reactions are considerably lower than the well-established 148 Nd(n,γ) 149 Nd → 149 Pm nuclear reaction, and so have not seen routine use for 149 Pm production.…”

Section: Promethium: 149 Pmmentioning

confidence: 99%

See 1 more Smart Citation

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i.e. a “one-size-fits-all” approach. This review will focus on recent progress and innovations in the area of Rare Earth radionuclides for theranostic applications by providing a detailed snapshot of their current state of production by means of nuclear reactions, subsequent promising theranostic capabilities in the clinic, as well as a discussion of factors that have impacted upon their progress through the theranostic drug development pipeline. Main body In light of this interest, a great deal of research has also been focussed towards certain under-utilised Rare Earth radionuclides with diverse and favourable decay characteristics which span the broad spectrum of most cancer imaging and therapeutic applications, with potential nuclides suitable for α-therapy (149Tb), β−-therapy (47Sc, 161Tb, 166Ho, 153Sm, 169Er, 149Pm, 143Pr, 170Tm), Auger electron (AE) therapy (161Tb, 135La, 165Er), positron emission tomography (43Sc, 44Sc, 149Tb, 152Tb, 132La, 133La), and single photon emission computed tomography (47Sc, 155Tb, 152Tb, 161Tb, 166Ho, 153Sm, 149Pm, 170Tm). For a number of the aforementioned radionuclides, their progression from ‘bench to bedside’ has been hamstrung by lack of availability due to production and purification methods requiring further optimisation. Conclusions In order to exploit the potential of these radionuclides, reliable and economical production and purification methods that provide the desired radionuclides in high yield and purity are required. With more reactors around the world being decommissioned in future, solutions to radionuclide production issues will likely be found in a greater focus on linear accelerator and cyclotron infrastructure and production methods, as well as mass separation methods. Recent progress towards the optimisation of these and other radionuclide production and purification methods has increased the feasibility of utilising Rare Earth radiometals in both preclinical and clinical settings, thereby placing them at the forefront of radiometals research for cancer theranostics.

show abstract